Modern approaches to mild and moderate bronchial asthma therapy in pediatrics

Abstract

Clinical efficacy and safety of sodium nedocromil (Tilade Mint) were studied in 90 children aged from 2 to 15 years suffering from mild to moderate bronchial asthma. The criteria for assessment were clinical dynamics, need for bronchodilators, lung function test and exacerbation frequency anamnestically. Moreover, we investigated different ways of the drug delivery in infants. As a result, clinical efficiency of 3-month basic therapy with Tilade Mint was shown in 90% of the children. Day and night asthma symptoms reduced in 5.5-6 times. The need for bronchodilators was decreased in 5 times. The drug inhalations averted airway limitation on exercise in the children. A length of stable asthma periods increased significantly. According to lung function test results as volume as flow parameters increased reliably. Most patients reached clinical and functional stability of the disease maintained for 3 months and longer in 66% of the patients. Only in 10% of the moderate asthma patients the basic therapy with Tilade Mint was not effective enough and they needed inhaled corticosteroids to be administrated. No one child had any adverse effects using Tilade Mint. The modern delivery systems permitted to apply this drug successfully even in very young children. Good tolerability and high effectiveness allow to consider sodium nedocromil (Tilade Mint) as the first-line drug for mild to moderate bronchial asthma children starting with ones of 2 years old.